These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 34101090)
1. Contemporary RNA Therapeutics for Glioblastoma. Melnick K; Dastmalchi F; Mitchell D; Rahman M; Sayour EJ Neuromolecular Med; 2022 Mar; 24(1):8-12. PubMed ID: 34101090 [TBL] [Abstract][Full Text] [Related]
2. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV Trials; 2018 May; 19(1):293. PubMed ID: 29801515 [TBL] [Abstract][Full Text] [Related]
4. DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE. Glavatskyi O; Khranovska N; Skachkova O; Gorbach O; Khmelnytskyi H; Shuba I; Pedachenko Y; Zemskova O; Zemskova O Exp Oncol; 2023 Dec; 45(3):282-296. PubMed ID: 38186026 [TBL] [Abstract][Full Text] [Related]
5. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients. Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. Hdeib A; Sloan AE CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330 [TBL] [Abstract][Full Text] [Related]
8. Vaccine-based immunotherapy for glioblastoma. Thomas AA; Fisher JL; Ernstoff MS; Fadul CE CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578 [TBL] [Abstract][Full Text] [Related]
9. Cellular-based immunotherapies for patients with glioblastoma multiforme. Xu X; Stockhammer F; Schmitt M Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481 [TBL] [Abstract][Full Text] [Related]
10. Current Immunotherapies for Glioblastoma Multiforme. Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H Front Immunol; 2020; 11():603911. PubMed ID: 33767690 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301 [TBL] [Abstract][Full Text] [Related]
12. Advances in Immunotherapy for Glioblastoma Multiforme. Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344 [TBL] [Abstract][Full Text] [Related]
13. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. Polyzoidis S; Tuazon J; Brazil L; Beaney R; Al-Sarraj ST; Doey L; Logan J; Hurwitz V; Jarosz J; Bhangoo R; Gullan R; Mijovic A; Richardson M; Farzaneh F; Ashkan K Br J Neurosurg; 2015 Apr; 29(2):197-205. PubMed ID: 25541743 [TBL] [Abstract][Full Text] [Related]
14. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?]. Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303 [TBL] [Abstract][Full Text] [Related]